EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

Last update 08 May 2025

Basic Info

Drugs associated with EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

VesiculoVax

Target

EBOV glycoprotein x LASV glycoprotein x MARV glycoprotein x SUDV glycoprotein

Mechanism

EBOV glycoprotein inhibitors [+3]

Active Org.

University of Texas Medical Branch [+1]

Originator Org.

Profectus BioSciences, Inc. [+1]

Active Indication

Hemorrhagic Fevers, Viral

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

100 Translational Medicine associated with EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

0 Patents (Medical) associated with EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

Literatures (Medical) associated with EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

09 Dec 2019·Journal of Clinical InvestigationQ1 · MEDICINE

Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death

Q1 · MEDICINE

Article

Author: Matassov, Demetrius ; Luckay, Amara ; Agans, Krystle N ; Fenton, Karla A ; Geisbert, Joan B ; Feldmann, Heinz ; Latham, Theresa E ; Hamm, Stefan ; Soukieh, Lena ; Geisbert, Thomas W ; Xu, Rong ; Eldridge, John H ; Witko, Susan E ; Mire, Chad E ; Gerardi, Cheryl S ; Ota-Setlik, Ayuko ; Deer, Daniel J ; Cross, Robert W ; Nowak, Rebecca M ; Happi, Christian

Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the boost vaccination with each of the 3 corresponding filoviruses (Ebola, Sudan, Marburg) or a heterologous contemporary lineage II strain of LASV. Serum IgG and neutralizing antibody responses specific for all 4 glycoproteins were detected in all vaccinated animals. A modest and balanced cell-mediated immune response specific for the glycoproteins was also detected in most of the vaccinated macaques. Regardless of the level of total glycoprotein-specific immune response detected after vaccination, all immunized animals were protected from disease and death following lethal challenges. These findings indicate that vaccination with attenuated rVSV vectors each expressing a single HF virus glycoprotein may provide protection against those filoviruses and LASV most commonly responsible for outbreaks of severe HF in Africa.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us: phs@patsnap.com

What we do

Drug
Clinical Progress
Patent
Literature
Report
News

EBOV glycoprotein x MARV glycoprotein x LASV glycoprotein x SUDV glycoprotein

Basic Info

Related

Analysis